Navigation Links
Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
Date:10/31/2009

SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia, PA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Mark A. Miller, M.D., head of the Division of Infectious Diseases, Chair of the Infection Prevention and Control Unit at the Jewish General Hospital in Montreal, Quebec, Canada, presented results showing that fidaxomicin is associated with faster resolution of diarrhea. In patients with more pronounced diarrhea (ie. not resolving in the first 24 hours of therapy), fidaxomicin was associated with a faster time to resolution of diarrhea than vancomycin (79 hours vs. 105 hours, p=0.056). It is possible that decreasing the duration of diarrhea may have a direct impact on reducing the spread of CDI in healthcare facilities and lowering overall environmental spore contamination, thereby decreasing CDI rates and leading to earlier discharge of CDI patients from the hospital.

In another presentation, Kathleen M. Mullane, D.O., an investigator from the University of Chicago, Department of Medicine, Section of Infectious Diseases, in Illinois, presented data that indicated fidaxomicin may be a more effective therapy for CDI in patients requiring concomitant antibiotics. Treatment of CDI is often complicated by systemic infections requiring concomitant antibiotics. The analysis indicated that in patients receiving concomitant antibiotics, those treated with fidaxomicin versus vancomycin, had a significantly improved global cure rate
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
3. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
4. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
5. AMDL Expands Drug Distribution in China With Additional Agreement, Valued at $2.3 Million Annually
6. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
7. iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology
8. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
9. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
10. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
11. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... Pharmaceuticals, Inc. (Nasdaq: ISTA ) today ... solution for dry eye) Phase 2 clinical study. ... endpoint of the objective sign of conjunctival staining ... achieved statistical significance on the objective sign of ...
... Results for Fourth Quarter Fiscal 2010 -- LAIYANG, China, Sept. 27 /PRNewswire-Asia-FirstCall/ -- ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, ...
... Pty. Ltd (Sydney, Australia) and The Garvan Institute ... they have entered into a license agreement in ... the Garvan Institute. Under the terms of the ... the Garvan,s proprietary cancer associated methylation DNA biomarkers ...
Cached Biology Technology:ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface 2ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface 3ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface 4Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 2Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 3Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 4Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 5Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 6Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010 7Clinical Genomics Pty Ltd and The Garvan Institute of Medical Research Enter into Licensing Agreement 2
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced ... Home Button Synaptics Fingerprint Sensor Technology Analysis" report ... Based on a totally different sensing ... first time a fingerprint sensor in its product. ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced ... 2015-2019" report to their offering. ... a technology used for the identification of individuals. Facial ... person such as nose, jaw edges, mouth, and the ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... its owner than a lost cat, according to two new studies. , ... of lost dogs were found, compared to just 53 percent of lost ... found by a call or visit to an animal shelter. More than ... license or identification tag at the time of its disappearance. , ...
... Medicine and Pharmacology at the University of California, San ... twin pairs over the past few years, which has ... many traits and genes, we have started to put ... variations in twins provides scientists with data on traits ...
... appears not to have extended to South American agriculture, ... , The University of Manchester researchers compared the DNA ... the mummy and at other sites in northwest Argentina ... , Surprisingly, they found both ancient and modern samples ...
Cached Biology News:Lost dogs found more often than lost cats, study suggests 2Lost dogs found more often than lost cats, study suggests 3Twin studies reveal genetic components leading to cardiac and kidney disease 2Twin studies reveal genetic components leading to cardiac and kidney disease 3
...
... purified recombinant human angiogenin expressed ... Physical form: Lyophilized from ... in phosphate buffered saline. ... WB. Titertest values: capture ...
Request Info...
2 ml SmartScan Racks...
Biology Products: